Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02846883 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of Allogeneic MSCs in Promoting T-regulatory Cells in Patients With Small Abdominal Aortic Aneurysms
A Phase 1 study, sponsored by VA Office of Research and Development.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT02846883: Clinical Trial Phase 1 study, sponsored by VA Office of Research and Development.
NCT02846883 is a Phase 1 study that was terminated before completion, run by VA Office of Research and Development. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02846883, a Phase 1 study, was terminated before completion, sponsored by VA Office of Research and Development.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This project is to determine the safety and explore the effectiveness of allogeneic (not cells of the participant but those of another human) mesenchymal stromal cells (MSCs) in decreasing inflammation and possible enlargement of the participants' abdominal aortic aneurysm. Participants will be selected as a possible subject because of an abdominal aortic aneurysm discovered on the ultrasound or computed tomographic ("CT") scan requested by the participants' doctor. The purpose of this study is to collect information that will be used to determine if MSCs can be used to decrease inflammation and possibly slow down enlargement of the participants' aneurysm. The investigators will also be collecting blood samples to study special inflammatory cells that cause aneurysms as well as asking participants to have a "PET" (positron emission tomography) scan that can measure inflammation directly in the participants' aneurysm.
Interventions
- DRUG Placebo
- BIOLOGICAL 1 million MSCs/kg
- BIOLOGICAL 3 million MSCs/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2016-12-05 |
| Est. Completion | 2021-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02846883
The ClinicalTrials.gov registry entry for NCT02846883 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02846883 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02846883 about?
NCT02846883 is a clinical study titled "Safety and Efficacy of Allogeneic MSCs in Promoting T-regulatory Cells in Patients With Small Abdominal Aortic Aneurysms". This project is to determine the safety and explore the effectiveness of allogeneic (not cells of the participant but those of another human) mesenchymal stromal cells (MSCs) in decreasing inflammation and possible enlargement of the participants' abdominal aortic aneurysm. Participants will be sele...
What is the current status of trial NCT02846883?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2016-12-05. Estimated completion is 2021-09-30.
What interventions are being tested in trial NCT02846883?
The interventions under investigation include: Placebo (DRUG), 1 million MSCs/kg (BIOLOGICAL), 3 million MSCs/kg (BIOLOGICAL).
Who is sponsoring clinical trial NCT02846883?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.